The enhancing effect of pyridostigmine on the gh response to ghrh undergoes an accelerated age-related reduction in down syndrome

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 5, 1996, Pages 288-292

  Arvat, E ^a   Gianotti, L ^a   Ragusa, L ^b   Valetto, M R ^a   Cappa, M ^c   Aimaretti, G ^a   Ramunni, J ^a   Grottoli, S ^a   Camanni, F ^a   Ghigo, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Down syndrome; Growth hormone; Growth hormone releasing hormone; Pyridostigmine

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; PYRIDOSTIGMINE; SERMORELIN; SOMATOMEDIN C; SOMATOSTATIN;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGING; ARTICLE; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOWN SYNDROME; GROWTH HORMONE RELEASE; HOT FLUSH; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOMATOSTATIN RELEASE;

ADOLESCENT; ADULT; AGING; CHILD; DOWN SYNDROME; DRUG SYNERGISM; GROWTH HORMONE-RELEASING HORMONE; HUMAN GROWTH HORMONE; HUMANS; PARASYMPATHOMIMETICS; PYRIDOSTIGMINE BROMIDE;

EID: 0029737737     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106894     Document Type: Article

References (30)

1. Ghigo E: Neurotransmitter control of GH secretion; in de la Cruz LF (ed): Regulation of Growth Hormone Secretion and Somatic Growth, Amsterdam, Excerpta Medica, 1992. pp 103-106.
2. Müller EE, Nistic ÖG: Neurotransmitter regulation of the anterior pituitary; in Müller EE, NisticÖ G (eds): Brain Messengers and the Pituitary, San Diego, Academic Press, 1989.
3. Dieguez C, Page MD, Scanlon MF: Growth hormone neuroregulation and its alterations in disease states, Clin Endocrinol (Oxf) 1988;28: 109-113.
4. Corpas E, Harman SH, Blackman MR: Human growth hormone and human aging, Endocr Rev 1993;14:20-39.
5. Ghigo E, Arvat E, Goffi S, Bellone J, Nicolosi M, Procopio M, Maccario M, Camanni F: Neural control of growth hormone secretion in aged humans; in Muller EE, Cocchi D, Locatelli V (eds): Growth Hormone and Somatomedins during Lifespan, Berlin, Springer, 1993.pp 275-287.
6. Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F: Growth hormone (GH) responsiveness to combined administration of arginine and GH-rcleasing hormone does not vary' with age in man, J Clin Endocrinol Metab 1990;71;1481-1485.
7. Ghigo E, Goffi S, Arvat E, Imperiale E, Boffa-no GM, Valetto MR, Mazza E, Santi I, Magliona A, Boghen MF, Boccuzzi G, Camanni F: A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging, J Endocrinol Invest 1992; 15: 665-670.
8. Ghigo E, Arvat E, Valentc F, Nicolosi M, Bof-lano GM, Procopio M, Belione J, Maccario M, Mazza E, Camanni F: Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults, Neuroendocrinology1991;54:291-294.
9. Sonntag WE, Forman LJ, Miki N: Effects of CNS active drugs and somatostatin antiserum on growth hormone release in young and old male rats, Neurocndocrinology 1981:33:73-78.
10. Ge F, Tsagarakis S, Rees LH, Bcsser GM, Grossman A: Relationship between growth hormone-releasing hormone and somatostatin in the rat: Effects of age and sex on content and in-vitro release from hypothalamic expiants, J Endocrinol 1989;123:53-58.
11. Locatelli V, Cella SG, Ccrmcnati P, Panzeri G, Scllan R, Muller EE: Defective growth hormone (GH) secretion in aging mammals: Contribution of central and peripheral inhibitory influences and of GH-relcasing hormone; in Valenti G (ed): Psychoncurocndocrinology of Aging: Basic and Clinical Aspects, Fidia Research Series, Padova, Liviana Press, 1989. vol 16. pp 61-67.
12. Ghigo E, Goffi S, Arvat E, Nicolosi M, Procopio M, Bellone J, Imperiale E, Mazza E, Baracchi G, Camanni F: Pyridostigmine partially restores the GH responsiveness to GHRH in normal aging, Acta Endocrinol 1990; 123:169-174.
13. Giustina A, Bussi AR, Conti C, Doga M, Legati F, Macca C, Zuccalo F, Wehrenberg WB: Comparative effect of galanin and pyridostigmine on the growth hormone response to growth hormone-releasing hormone in normal aged subjects, Horm Res 1992:37:165-170.
14. White P, Hiley CR, Goodhardl MJ: Ncocorti-cal cholinergic neurons in elderly people, Lancet 1977;1:668-671.
15. Barthus RT, Dean RL, Beer B, Lippa A: The cholinergic hypothesis of geriatric memory dysfunction, Science 1982.217:408-417.
16. Ghigo E, Nicolosi M, Arvat E, Marcone A, Danelon F, Mucci M, Franceschi M, Smime S, Camanni F: Growth hormone secretion in Alzheimer's disease: Studies with growth hormone-releasing hormone alone and combined with pyridostigmine or arginine, Dementia 1993;4:315-320.
17. Rossor MN: Dementia, Lancet 1982;2: 1200-1204.
18. Wisniewski KE, Howe J, Williams DG, Wisniewski HM: Precocious aging and dementia in patients with Down's syndrome, Biol Psychiatry 1978;13:619-627.
19. Williams RS, Matthyssc S, Swaab DF, Fliers E, Mirmiran M, Van Gool WA, Van Haaren F: Age-related changes in Down syndrome brain and the cellular pathology of Alzheimer disease, Prog Brain Res 1986;70(4):49-67.
20. Yates CM, Simpson J, Maloney AFJ, Gordon A, Reid AH: Alzheimer-like cholinergic deficiency in Down’s syndrome, Lancet 1980;2: 39-40.
21. Wisniewski KE, Bobinski M: Hypothalamic abnormalities in Down's syndrome; in Epstein CJ (ed): The morphogenesis of Down’s syndrome, New York, Wiley-Liss, 1991. pp213-218.
22. Katz CM, Taylor PM: Incidence of low birth weight in children with severe mental retardation, Am J Dis Child 1967; 114:80-87.
23. Cronk C, Crocker AC, Pucschcl SM, Shea AM, Zackai E, Pickens G, Reed RB: Growth charts for children with Down's syndrome: 1 month to 18 years of age, Pediatrics 1988:81:102-110.
24. Torrado C, Castells S: Diagnosis of hypothalamic dysfunction in Down's syndrome producing growth hormone deficiency; in Castells C, Wisniewski KE (eds): Growth Hormone Treatment in Down's Syndrome, Chichester, Wiley &Sons, 1993. pp 55-71.
25. Castells S, Torrado C, Bastian W, Wisniewski KE: Growth hormone deficiency in Down's syndrome children, J Intellect Disabil Res 1992;36:29-43.
26. Barreca A, Rasorc Quartino A, Acutis MS, Ponzani P, Dämonie G, Miami E, Balestra V, Giordano G, Minuto F: Assessment of growth hormone insulin-like growth factor 1 axis in Down’s syndrome, J Endocrinol Invest 1994: 17:431-436.
27. Sara VR, Gustavson KH, Amuren G, Hall K, Wcllcrbcrg L: Somatomedins in Down's syndrome, Biol Psychiatry 1983;18:803-811.
28. Anncrcn G, Gustafsson J, Sara VR, Tuvcmo T: Normalized growth velocity in children with Down's syndrome during growth hormone therapy, J Intellect Disabil Res 1993:37:381-387.
29. Castells S, Bclicau I, Wisniewski KE: Long term effects of recombinant human growth hormone (rhGH) on children with Down's syndrome with short stature; in Castells S, Wisniewski KE(cds): Growth HormoncTrcatmenl in Down's Syndrome, Chichester, Wiley &Sons, 1993. pp 163-182.
30. Ragusa L, Alberti A, Proto C, Romano C, Cola-bucci F: Preliminary results after one year of recombinant human growth hormone treatment in four subjects with Down’s syndrome; in Castells S, Wisnicw’ski KE (eds): Growth Hormone Treatment in Down's Syndrome, Chichester, Wiley &Sons 1993. pp 199-202.